FDA: Authorizes Libre Duo 10 Day Continuous Monitor, First Dual Glucose-Ketone

• The U.S. Food and Drug Administration recently authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for individuals aged two and older with diabetes.
• This device is the first wearable in the U.S. to continuously monitor ketone levels and the first globally to continuously track both glucose and ketones in a single unit.
• The authorization, granted through the FDA De Novo medical device pathway, establishes new special controls for device labeling and performance testing.
• The system provides real-time data and alerts to a smartphone, enabling early detection of rising ketone levels to help prevent diabetic ketoacidosis (DKA).
• Its development was expedited by an earlier FDA Breakthrough Device designation, recognizing its potential for life-threatening conditions.

Having real-time, round-the-clock information on rising ketone levels can be pivotal, often distinguishing between the opportunity for early intervention and the onset of a critical, life-threatening emergency.

The U.S. Food and Drug Administration (FDA) recently granted authorization for the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System, a significant advancement for individuals aged two years and older living with diabetes. This innovative device represents a pioneering achievement, being the first wearable technology available in the United States capable of continuously tracking ketone levels. Furthermore, it stands as the world's inaugural device designed to continuously monitor both blood sugar (glucose) and ketones simultaneously within a single unit. This FDA authorization of the Libre Duo 10 Day continuous monitor marks a new era in diabetes management.

Michelle Tarver, M.D., Ph.D., who serves as the Director of the FDA’s Center for Devices and Radiological Health, underscored the profound impact of this development. She characterized the authorization as a "breakthrough" for enhancing the safety of both children and adults affected by diabetes. Dr. Tarver emphasized that having real-time, round-the-clock information on rising ketone levels can be pivotal, often distinguishing between the opportunity for early intervention and the onset of a critical, life-threatening emergency. This sentiment highlights the device's potential to transform proactive health management for diabetic patients.

Diabetes affects an estimated 40.1 million Americans, according to data from the Centers for Disease Control and Prevention, necessitating diligent management of blood sugar levels. For the approximately 2.1 million Americans living with type 1 diabetes, however, glucose monitoring alone provides only a partial picture of their metabolic health. A serious complication known as diabetic ketoacidosis (DKA) can arise when the body produces excessive ketones, a byproduct of burning fat for energy instead of glucose. DKA can progress rapidly and become life-threatening if not addressed promptly, making the early detection of elevated ketone levels critically important.

Historically, individuals requiring ketone monitoring relied on separate tests that offered only a single measurement at a specific moment, failing to indicate whether ketone levels were increasing or decreasing. The Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System effectively bridges this crucial gap. It continuously measures both ketone and glucose concentrations in the interstitial fluid just beneath the skin, providing minute-by-minute data throughout the day and night. This continuous ketone glucose monitoring system wirelessly transmits readings to a compatible smartphone, where users can observe their current levels and discern trends, such as whether levels are rising or falling. The system is also equipped to issue automatic alerts when ketone levels reach a concerning threshold, a feature designed to help patients and caregivers identify escalating ketones before DKA prevention becomes an urgent medical necessity. It is important to note that ketone information should always be interpreted in conjunction with glucose readings and other symptoms.

The FDA's decision to grant marketing authorization to Abbott Diabetes Care for the Libre Duo 10 Day followed a comprehensive review of extensive clinical and performance data. The clinical program involved six studies with over 600 participants aged two years and older, meticulously evaluating the device's accuracy in monitoring both ketone and glucose across various concentration ranges. These studies confirmed the device's capability to precisely track clinically significant changes in ketone levels over its 10-day wear period, including the vital identification of elevated ketones prior to the onset of diabetic ketoacidosis. This Abbott Diabetes Care authorization also aligns with the FDA’s Home as a Health Care Hub Initiative, which promotes the development of patient-centric devices suitable for home use.

Prior to receiving full authorization, the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System was granted an FDA Breakthrough Device designation. This designation is specifically designed to accelerate the development and review process for medical devices that offer more effective treatment or diagnostic capabilities for conditions that are life-threatening or irreversibly debilitating. The final marketing authorization was issued through the FDA De Novo medical device pathway, a regulatory route established for novel, low- to moderate-risk devices. Crucially, alongside this De Novo authorization, the FDA is establishing specific "special controls." These controls will define precise requirements related to the device's labeling and performance testing. Adherence to these special controls, in combination with general controls, is intended to provide a robust assurance of the device's safety and effectiveness. This precedent-setting authorization and the accompanying special controls will significantly influence future regulatory submissions and product development within the continuous dual monitoring sector.

This FDA authorization establishes a new class of medical devices and sets specific 'special controls' for labeling and performance. Lawyers advising medical device companies or compliance officers in this sector should review these controls as they will guide future product development, marketing, and regulatory submissions for similar continuous dual-monitoring systems, especially those targeting at-home use and DKA prevention.

Source: Original reporting via FDA press release